Mystic Asset Management Inc. Purchases 25,555 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Mystic Asset Management Inc. raised its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 8.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 338,902 shares of the company's stock after acquiring an additional 25,555 shares during the quarter. Mystic Asset Management Inc. owned approximately 0.62% of Zevra Therapeutics worth $2,538,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. raised its holdings in shares of Zevra Therapeutics by 462.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after purchasing an additional 3,001,000 shares during the period. AIGH Capital Management LLC acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth $6,577,000. Barclays PLC raised its holdings in shares of Zevra Therapeutics by 402.9% during the fourth quarter. Barclays PLC now owns 289,688 shares of the company's stock worth $2,416,000 after purchasing an additional 232,089 shares during the period. Altium Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 8.8% during the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after purchasing an additional 150,000 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 13.8% during the fourth quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after purchasing an additional 144,256 shares during the period. 35.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZVRA. Cantor Fitzgerald increased their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. HC Wainwright started coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price on the stock. Wall Street Zen cut shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Stock Down 4.7%

ZVRA traded down $0.59 on Friday, reaching $12.07. 1,200,309 shares of the company traded hands, compared to its average volume of 738,236. The stock's 50 day moving average price is $9.54 and its 200-day moving average price is $8.35. Zevra Therapeutics, Inc. has a 52-week low of $5.45 and a 52-week high of $13.16. The company has a market cap of $659.99 million, a price-to-earnings ratio of -6.35 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The business had revenue of $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. During the same period in the previous year, the company earned ($0.40) earnings per share. On average, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.